StockData
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Corp. (KTTA) stock

KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.48−0.00 (-0.48%)

Close on Nov 20, 2026Market cap $16.00MP/E –Yield –

Pasithea Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Pasithea Therapeutics's revenue for the twelve months ending Dec 31, 2022 was $486.56K. For fiscal 2022 it was $486.56K, up 3130.4% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2022Dec 31, 2022$486.56K+3130.4%
FY2021Dec 31, 2021$15.06K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022$240.71K–
Q3 FY2022Sep 30, 2022$218.61K–
Q2 FY2022Jun 30, 2022$13.58K–
Q1 FY2022Mar 31, 2022$13.66K–

More Pasithea Therapeutics figures

See a number that looks wrong?